PMID- 9267826
OWN - NLM
STAT- MEDLINE
DCOM- 19971014
LR  - 20141120
IS  - 0893-3952 (Print)
IS  - 0893-3952 (Linking)
VI  - 10
IP  - 8
DP  - 1997 Aug
TI  - Identification of HER-2/neu oncogene amplification by fluorescence in situ 
      hybridization in stage I endometrial carcinoma.
PG  - 823-31
AB  - Prognostic factors capable of detecting potential for aggressive disease in early 
      stage endometrial cancer might be useful in selecting patients for early adjuvant 
      therapy. Sixty-three patients with surgical Stage I endometrial carcinoma treated 
      by hysterectomy with a mean follow-up of 55 months were evaluated for tumor type, 
      grade, depth of myometrial invasion, presence of vascular invasion, DNA ploidy, 
      and HER-2/neu overexpression by immunohistochemical techniques. These results 
      were compared with HER-2/neu gene amplifications evaluated by fluorescence in 
      situ hybridization (FISH) and their ability to predict disease survival. For 
      FISH, sections 5 microns thick of formalin-fixed, paraffin-embedded tissues were 
      processed using the Oncor Chromosome In Situ Hybridization System. Automated 
      hybridization using the Ventana Gen was performed with the Oncor unique sequence 
      digoxigenin-labeled HER-2/neu DNA probe. Gene copy numbers were evaluated using 
      the Zeiss Axioskop50 fluorescence microscope. HER-2/neu amplification was noted 
      in 24 (38%) of 63 cases. By multivariate analysis, only aneuploidy (P = .04) and 
      HER-2/neu amplification by FISH (P = .04) independently correlated with survival. 
      Although we saw a relationship between HER-2/neu protein expression and gene 
      amplification, this trend did not achieve statistical significance. HER-2/neu 
      oncogene amplification can be assessed using automated FISH on formalin-fixed, 
      paraffin-embedded tissue. HER-2/ neu amplification predicts poor outcome in Stage 
      I endometrial cancer. HER-2/neu amplification status has potential use in the 
      identification of patients with high risk of disease recurrence who might benefit 
      from intensified therapy.
FAU - Riben, M W
AU  - Riben MW
AD  - Department of Pathology, Albany Medical Center, New York 12208, USA.
FAU - Malfetano, J H
AU  - Malfetano JH
FAU - Nazeer, T
AU  - Nazeer T
FAU - Muraca, P J
AU  - Muraca PJ
FAU - Ambros, R A
AU  - Ambros RA
FAU - Ross, J S
AU  - Ross JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aneuploidy
MH  - Endometrial Neoplasms/diagnosis/*genetics/metabolism/mortality
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Survival Rate
EDAT- 1997/08/01 00:00
MHDA- 1997/08/01 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1997/08/01 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
PST - ppublish
SO  - Mod Pathol. 1997 Aug;10(8):823-31.